The E6 and E7 HPV viral proteins inhibit the p53 and p105-RB proteins (binding partners of p16), respectively, in HPV+ tumors, thereby making genetic mutations of TP53 and CDKN2A uncommon in these carcinomas [6,8]. Here, TP53 is linked to carcinoma.